Advertisement
Screener

AIM IMMUNOTECH INC. (AIM) Long-Term Debt, Maturity, Year Two

2.8 / 5 stars · 68/120 Roast Me

AIM IMMUNOTECH INC. Long-Term Debt, Maturity, Year Two

AIM IMMUNOTECH INC. (AIM) had Long-Term Debt, Maturity, Year Two of $588.00 thousand as of 2026-03-31, per its 10-Q filed 2026-05-15.

Financial Statements › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity

us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo · last filed 2026-08-07

  • 2026-03-31: Long-Term Debt, Maturity, Year Two $588.00K.
  • 2025-12-31: Long-Term Debt, Maturity, Year Two $927.00K.
Period endLong-Term Debt, Maturity, Year Two
2026-03-31$588.00K
10-Q · filed 2026-05-15
2025-12-31$927.00K
10-Q · filed 2026-08-07

Similar stocks

Stock NameCountryMarket CapPE Ratio
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)United States$0.006B
CERO THERAPEUTICS HOLDINGS, INC. (CERO)United States$0.007B
PharmaCyte Biotech, Inc. (PMCB)United States$0.005B
TScan Therapeutics, Inc. (TCRX)United States$0.008B-1.23
WINDTREE THERAPEUTICS INC /DE/ (WINT)United States$0.003B-0.32
VivoSim Labs, INC. (VIVS)United States$0.003B
Calidi Biotherapeutics, Inc. (CLDI)United States$0.003B
CURIS INC (CRIS)United States$0.002B-0.05
Senti Biosciences Holdings, Inc. (SNTI)United States$0.011B-0.70
Silexion Therapeutics Corp (SLXN)$0.001B